Valuation: Harbin Gloria Pharmaceuticals Co., Ltd

Market Cap 6.47B 972M 873M 804M 728M 1.36B 92.28B 1.38B 9.57B 3.83B 48.66B 3.65B 3.57B 153B P/E 2024
24.2x
P/E 2025 18.2x
Enterprise Value 5.63B 846M 760M 699M 633M 1.18B 80.32B 1.2B 8.33B 3.34B 42.35B 3.17B 3.11B 133B EV / Sales 2024
2.12x
EV / Sales 2025 2.82x
Free-Float
90.2%
Yield 2024 *
-
Yield 2025 -
Aug. 26 HARBIN GLORIA PHARMACEUTICALS Co., LTD Reports Earnings Results for the Half Year Ended June 30, 2026 CI
Apr. 27 HARBIN GLORIA PHARMACEUTICALS Co., LTD Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
Apr. 14 HARBIN GLORIA PHARMACEUTICALS Co., LTD Reports Earnings Results for the Full Year Ended December 31, 2025 CI
Jan. 15 Harbin Gloria Pharmaceuticals Co., Ltd Approves Election of Xu Yuhong as Independent Director, Effective 14 January 2026 CI
25-10-28 HARBIN GLORIA PHARMACEUTICALS Co., LTD Reports Earnings Results for the Nine Months Ended September 30, 2025 CI
25-08-26 HARBIN GLORIA PHARMACEUTICALS Co., LTD Reports Earnings Results for the Half Year Ended June 30, 2025 CI
25-06-04 Harbin Gloria Pharmaceuticals Gets Right to Market Eisai's Mecobalamin Injection MT
25-05-27 Harbin Gloria Pharmaceuticals Signs Co-Promotion Deal for Lipid Drug MT
25-04-25 HARBIN GLORIA PHARMACEUTICALS Co., LTD Reports Earnings Results for the First Quarter Ended March 31, 2025 CI
25-03-17 HARBIN GLORIA PHARMACEUTICALS Co., LTD Elects Liu Yueyin as A Non-Independent Director CI
25-03-14 Tranche Update on HARBIN GLORIA PHARMACEUTICALS Co., LTD's Equity Buyback Plan announced on October 22, 2024. CI
25-03-12 HARBIN GLORIA PHARMACEUTICALS Co., LTD's Equity Buyback announced on October 22, 2024, has closed with 32,307,224 shares, representing 1.42% for CNY 79.99 million. CI
25-03-10 Tranche Update on HARBIN GLORIA PHARMACEUTICALS Co., LTD's Equity Buyback Plan announced on October 22, 2024. CI
1 day+0.69%
1 week-4.61%
Current month-20.55%
1 month-16.43%
3 months+0.69%
6 months-19.89%
Current year-5.54%
1 week 2.8
Extreme 2.8
3.05
1 month 2.8
Extreme 2.8
3.78
Current year 2.37
Extreme 2.37
5.1
1 year 2.37
Extreme 2.37
5.1
3 years 1.66
Extreme 1.66
5.1
5 years 1.66
Extreme 1.66
5.1
10 years 1.66
Extreme 1.66
9.8
Manager TitleAgeSince
Chief Executive Officer 53 2022-12-25
Corporate Officer/Principal 42 2018-04-17
Corporate Officer/Principal 40 2019-05-22
Director TitleAgeSince
Director/Board Member 53 2022-11-10
Director/Board Member 40 2025-03-13
Chairman 47 2025-02-05
Date Insider Type Main position Quantity % Market Cap. Importance
7/2/25 Sell 587,500 0.0283%
7/2/25 Sell

Director

259,600 0.0125%
7/2/25 Sell 587,500 0.0283%
Change 5-day change 1-year change 3-year change Capi.($)
+0.69%-4.61%-13.17%+19.34% 964M
+3.19%+8.48%+74.25%+153.03% 1,224B
-0.73%+2.09%+46.41%+87.64% 662B
+1.41%+3.40%+30.98%+112.26% 514B
+0.42%+2.88%+54.92%+69.67% 388B
+2.18%+1.55%+72.70%+45.42% 361B
+1.12%+3.80%+35.82%+59.72% 302B
+6.96%+7.55%+11.15%+37.89% 271B
+1.15%+4.19%+59.72%+78.16% 249B
+3.06%+8.58%+44.03%+122.76% 205B
Average +1.72%+1.97%+41.68%+78.59% 417.78B
Weighted average by Cap. +1.19%+3.04%+53.34%+100.40%

Financials

2024 2025
Net sales 2.44B 367M 330M 303M 275M 513M 34.83B 522M 3.61B 1.45B 18.37B 1.38B 1.35B 57.79B 2.14B 321M 288M 265M 240M 449M 30.47B 457M 3.16B 1.27B 16.07B 1.2B 1.18B 50.56B
Net income 233M 34.98M 31.43M 28.92M 26.19M 48.89M 3.32B 49.76M 345M 138M 1.75B 131M 128M 5.51B 377M 56.65M 50.9M 46.83M 42.41M 79.16M 5.38B 80.58M 558M 223M 2.84B 213M 208M 8.92B
Net Debt -509M -76.46M -68.69M -63.21M -57.24M -107M -7.26B -109M -753M -301M -3.83B -287M -281M -12.04B -838M -126M -113M -104M -94.29M -176M -11.96B -179M -1.24B -497M -6.31B -473M -463M -19.84B
Projected Income Statement - Annual - Harbin Gloria Pharmaceuticals Co., Ltd
Logo Harbin Gloria Pharmaceuticals Co., Ltd
HARBIN GLORIA PHARMACEUTICALS Co Ltd is a China-based company principally engaged in the research, development, production and sale of pharmaceuticals. The Company operates its businesses through three segments. The Traditional Chinese Medicine segment's main product is Annao Pills and Tablets. The Chemical Pharmaceuticals segment's products include cardiovascular and cerebrovascular drugs, musculoskeletal drugs, vitamins, electrolytes, analgesics, anti-infectives, anti-tumor drugs and others. The Others segment engages in pharmaceutical research and development, clinical services and others. The Company distributes its products within the domestic market and to overseas markets.
Employees
2,350
Date Price Change Volume
26-10-30 CN¥2.900 +0.69% 211,232,193
26-10-29 CN¥2.880 -2.37% 117,068,100
26-10-28 CN¥2.950 +1.37% 142,305,478
26-10-27 CN¥2.910 -3.32% 118,166,342
26-10-26 CN¥3.010 -2.27% 136,398,152

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Harbin Gloria Pharmaceuticals Co., Ltd
  1. Stock Market
  2. Stocks
  3. 002437 Stock